Ligand Pharmaceuticals to Participate in Investor Conferences to Boost Visibility and Growth

Ligand Pharmaceuticals will participate in the Citi 20th Annual BioPharma Conference and the H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO and CFO will present the business model and host one-on-one meetings with investors. Ligand's diversified business model and strategic alliances provide a strong foundation for growth, but dependence on partnerships and market competition pose risks. The company's participation in these conferences is a strategic move to bolster investor confidence and attract new investments.

Title: Ligand Pharmaceuticals to Engage Investors at Upcoming Conferences

JUPITER, Fla., Aug. 19, 2025 — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced that its Chief Executive Officer, Todd Davis, and Chief Financial Officer, Tavo Espinoza, will participate in the Citi 20th Annual BioPharma Conference in Boston and the H.C. Wainwright 27th Annual Global Investment Conference in New York. These events are scheduled for September 3 and 9, 2025, respectively [1].

The company's participation in these conferences is part of a strategic effort to engage with investors and provide insights into its business model. Ligand's business model is built on supporting the clinical development of high-value medicines through financing and licensing technologies. The company aims to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams [2].

During the Citi conference, Davis and Espinoza will participate in a fireside chat on September 3, 2025, at 11:15 a.m. ET. At the H.C. Wainwright conference, they will present on September 9, 2025, at 1:00 p.m. ET. One-on-one meetings with investors will be available during these conferences, and interested parties are encouraged to contact their Citi or H.C. Wainwright representative to arrange such meetings [1].

Ligand's diversified business model, which includes partnerships with leading pharmaceutical companies such as Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International, provides a strong foundation for growth. However, the company's dependence on these partnerships and market competition poses potential risks. By participating in these conferences, Ligand seeks to bolster investor confidence and attract new investments [2].

Ligand's strategic alliances and technology platforms, such as Captisol® and NITRICIL™, are designed to optimize drug solubility, stability, and dosing profiles. These technologies are integral to Ligand's business model and have the potential to drive revenue growth [2].

Investors are encouraged to monitor Ligand's investor relations website and social media channels for updates and disclosures. For more information, please visit www.ligand.com or contact Melanie Herman at investors@ligand.com [1].

References
[1] Ligand Pharmaceuticals Incorporated. (2025, Aug. 19). Ligand to Participate in September Investor Conferences. Retrieved from https://investor.ligand.com/news-and-events/press-releases/news-details/2025/Ligand-to-Participate-in-September-Investor-Conferences/default.aspx
[2] Biospace. (2025, Aug. 19). Ligand to Participate in September 2025 Investor Conferences. Retrieved from https://www.biospace.com/press-releases/ligand-to-participate-in-september-2025-investor-conferences